Cyclooxgenase (COX) inhibitor; displays selectivity for COX-1 (IC50 values are 230 and 630 nM for human COX-1 and COX-2 respectively). Widely used anti-inflammatory agent.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|ethanol||17.89||50 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 357.79. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.79 mL||13.97 mL||27.95 mL|
|5 mM||0.56 mL||2.79 mL||5.59 mL|
|10 mM||0.28 mL||1.4 mL||2.79 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
References are publications that support the biological activity of the product.
Palomer et al (2002) Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J.Med.Chem. 45 1402 PMID: 11906281
Shen and Winter (1977) Chemical and biological studies on indomethacin, sulindac and their analogs. Adv.Drug Res. 12 90 PMID: 343530
Walters and Willoughby (1965) Indomethacin, a new anti-inflammatory drug: its potential use as a laboratory tool. J.Pathol.Bacteriol. 90 641 PMID: 5849618
If you know of a relevant reference for Indomethacin, please let us know.
View Related Products by Product Action
Keywords: Indomethacin, Indomethacin supplier, Cyclooxygenase, inhibitors, inhibits, COX-1, COX-2, Oxygenases, Oxidases, 1708, Tocris Bioscience
6 Citations for Indomethacin
Citations are publications that use Tocris products. Selected citations for Indomethacin include:
Gonnermann et al (2015) Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity. Oncoimmunology 4 e988460 PMID: 25949900
Tang et al (2014) Lactate-mediated glia-neuronal signalling in the mammalian brain. Nat Commun 5 3284 PMID: 24518663
Cramer et al (2015) Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse. J Biomed Sci 35 5664 PMID: 25855180
Miller et al (2012) CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A 109 20602 PMID: 23185004
Flamm et al (2012) Multiscale prediction of patient-specific platelet function under flow. Blood 120 190 PMID: 22517902
Allen et al (2015) DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation. Front Oncol 5 260 PMID: 26697402
Do you know of a great paper that uses Indomethacin from Tocris? Please let us know.
Reviews for Indomethacin
There are currently no reviews for this product. Be the first to review Indomethacin and earn rewards!
Have you used Indomethacin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.